臺大基因體暨蛋白體醫學研究所（基蛋所）

Home
Taiwan
Zhongshan District
臺大基因體暨蛋白體醫學研究所（基蛋所）

歡迎加入臺大基蛋所，和我們一起探索轉譯醫學的奧秘^^

於基因科學相關之領域之中，本校已具有相關之研究及教育資源，如醫學院、生命科學院、生物資源暨農學院、及電機工程學院等其他相關跨領域之學院與系所、以及新近籌設之基因體醫學中心等等，確實已提供極為廣泛之基因科學相關研究能量及培育人才，但基因體暨蛋白體醫學研究所之成立及運作，將進一步提升各研究單位基因醫學相關之跨領域合作，並和臺大醫院充沛之優勢臨床研究能量與基礎相關學科之間充分結合，如此絕對能進一步提升臺大於基因醫學相關領域之發展及確立領導龍頭之地位。為補強各基因科學研究單位及臨床單位由於在專業背景及需求上之需求差異性所造成之互動及溝通不足，基因體暨蛋白體醫學研究所之成立雖然無法滿足基因科學相關領域所有的需求，卻能有助於解決上述之困境，並於臺大各學院間基因科學相關研究之橫向及縱向跨領域整合之中，扮演關鍵性的角色。

有別於其他臨床或基礎學科，本所以培育跨領域之臨床基因醫學研究領導人才為首要目標。

為新一代、來自各種不同領域之專才提供量身訂製、涵蓋各領域之臨床基因醫學教育。使其在研究所的訓練中，具備臨床基因醫學應用、研發的知識、跨領域溝通學習的經驗及領導能力。這些領導人才將是國家競爭力中最重要的無形資產，將來可在社會的不同崗位上貢獻其智慧，帶領各種形式的團隊，共同為提昇臨床基因醫學的國際競爭力及打造臺灣成為全球生物醫學重鎮而努力。

本所研究方向：由基因體學及蛋白體學研究的角度出發，進行以臨床應用為導向之轉譯醫學研究。

21/04/2026

嗨大家好，
本所陳佑宗所長將於 5/14 邀請目前於 Caltech 從事博士後研究的陳敦元博士至醫學院演講。陳博士的研究聚焦於早期胚胎發育，特別是胚胎在著床（implantation）過程中，如何建立前後軸（anterior-posterior axis）以及胎盤命運的決定，這些都是發育生物學中相當核心且關鍵的問題。

陳博士為台大畢業生，之後於 UC Berkeley 完成博士訓練，目前於 Caltech 進行博士後研究，並與美國 IVF clinic 有合作，研究同時涵蓋基礎機制與人類胚胎相關議題。CV:https://www.dongyuanchen.com/

📌 演講資訊
講題：The Womb Where It Happens: Establishing the Anterior-Posterior Axis and Placental Identity at Implantation

時間：5/14（四）12:15–13:15

地點：基醫202

另外，考量陳博士仍處於相對年輕的學術階段，與大家的距離其實不遠，我們也特別安排了一場輕鬆的交流時間，讓大家可以近距離聊聊他的求學與研究歷程，作為未來規劃的參考。

🍽️ 學生交流（備有餐點，需事先報名）
時間：5/14（四）11:00–12:00（演講前）
地點：1303 幸福講堂
報名連結：
https://docs.google.com/forms/d/e/1FAIpQLSdmTmGlzoGJqvd7ab3s4sO1b3PfCkHB3oPcXavp0Q5Td4cOfw/viewform?usp=header

歡迎大家一起來參加！

14/04/2026

📣5/11演講歡迎踴躍參加📣

[講題]：Imaging and Multiomics Reveal Early Network and Metabolic Dysfunction in Preclinical Models of Alzheimer's Disease

[講者]：陳儀莊所長（中研院生物醫學研究所）

CV:https://www.mc.ntu.edu.tw/medgenpro/News.action?q_type=-1&q_itemCode=11673

[時間]：2026/5/11 (星期一) 上午11：20-12：10

[Hybrid Meeting]:
*地點: 醫學院基醫大樓202講堂
*Webex:

https://ntumc.webex.com/ntumc-tc/j.php?MTID=m8ad5a9f0d3e4bd0dbfc68d56f560fffc

[摘要]：

Alzheimer's disease remains a major unmet medical need, with few effective disease-modifying therapies. To identify early mechanisms and therapeutic opportunities, we use preclinical models of Alzheimer's disease and an integrative approach that combines brain imaging with multiomic analyses. Using diffusion tensor imaging (DTI), we detect early disruption of hippocampal-prefrontal connectivity before overt disease onset. Multiomic analyses further reveal coordinated changes in lipid metabolism and glial support pathways, pointing to impaired network maintenance as a key feature of disease progression. We focus on adenosine signaling as a central regulator. Pharmacological inhibition of ENT1 restores metabolic homeostasis, improves network connectivity, and reduces pathological changes. Together, these findings support a model in which energy imbalance drives neurodegeneration across multiple cell types and highlight new opportunities for disease-modifying intervention.

歡迎踴躍參加！

◎每月精彩演講已放到網路上囉，歡迎大家一起來重溫精彩內容！http://speech.ntu.edu.tw/ntuspeech/Cate/index/id-3

◎歡迎加入演講FB社團，掌握最新演講消息：Medical Genetics & Genomics Monthly Seminar https://www.facebook.com/groups/1109733759041652/

臺大基蛋所與臺大醫院基因醫學部敬邀

30/03/2026

📣4/13演講歡迎踴躍參加📣

[講題]：From Germ Theory to Germ Therapy: Revisit of Koch's Postulates

[講者]：吳明賢院長（臺大醫學院）
CV：https://www.mc.ntu.edu.tw/medgenpro/News.action?q_type=-1&q_itemCode=11553

[時間]：2026/4/13 (星期一) 上午11：20-12：10

[Hybrid Meeting]:
*地點: 醫學院基醫大樓202講堂
*Webex: https://ntumc.webex.com/ntumc-tc/j.php?MTID=m6df73b295528806545ecc717b3b7dded

[摘要]：
荷蘭約雷文虎克(Antoinivan Leeuwenhoek)發明顯微鏡，法國巴斯德(Louis Pasteur)發現微生物與酒精醱酵的關係，促成德國柯霍建立準則(Postulates)及細菌致病學說(Germ Theory)，進而確認一些疾病的產生與微生物的感染有關。我們的研究從幽門桿菌(Helicobacter pylori)出發，探討同一細菌的慢性感染導致慢性胃炎、消化性潰瘍、胃癌及胃淋巴癌的致病機轉，並進行大規模臨床試驗找出抗藥性最低的處方進行除菌治療。
進一步以在社區篩檢幽門桿菌並根除來預防潰瘍及胃癌的發生，証實可減少消化性潰瘍和胃癌發生率與死亡率，並以實証做成國際篩檢幽門桿菌預防胃癌準則及共識的發表。從幽門桿菌出發，我們團隊進一步擴展到腸道微菌(Gut Microbiota)與健康和疾病的研究，發現腸道生態的失衡(Dysbiosis)與健康和慢性疾病及癌症息息相關，有潛力作為未來診斷、治療和預防的標的。腸道生態並不是封閉的小宇宙，而是與宿主基因組成、飲食、代謝和免疫系統緊密交織的巨大網路，未來的研究不應再只是單純分析菌種清單，而是同時整合物種組成、代謝產物、基因功能與互動網路。

歡迎踴躍參加！

◎每月精彩演講已放到網路上囉，歡迎大家一起來重溫精彩內容！http://speech.ntu.edu.tw/ntuspeech/Cate/index/id-3

◎歡迎加入演講FB社團，掌握最新演講消息：Medical Genetics & Genomics Monthly Seminar https://www.facebook.com/groups/1109733759041652/

臺大基蛋所與臺大醫院基因醫學部敬邀

10/03/2026

115學年度基蛋所「博士班一般入學考試」招生開始囉！

✍️報名網址：https://exam.aca.ntu.edu.tw/grad/index.asp

🫶名額：2名

😀竭誠的歡迎你加入本所，與我們一起探尋轉譯醫學的奧妙！！

✍️欲報名者請於3月24日上午9時起，至3月31日晚上24時止索取繳款帳號並繳費，再上網登錄報名資料，於4月1日下午5時前依規定上傳備審資料。

👍本所官網：https://www.mc.ntu.edu.tw/medgenpro/Index.action

02/03/2026

📣3/9演講歡迎踴躍參加📣

[講題]：Practical implementation and challenges of molecular testing in clinical oncology

[講者]：李日翔主任（新竹台大分院腫瘤醫學部）
CV：https://www.mc.ntu.edu.tw/medgenpro/News.action?q_type=-1&q_itemCode=11405

[時間]：2026/3/9　（星期一）上午11：20-12：10

[Hybrid Meeting]:
*地點: 醫學院基醫大樓202講堂
*Webex:
https://ntumc.webex.com/ntumc-tc/j.php?MTID=m3fc08de3f7085816d9072504e14f7e84

[摘要]：
Molecular testing has been the standard in daily oncology practice. Multiple factors shall be taken in to consideration prior to conducting the test, including the timing, the NGS platform, quality and quantity of samples, interpretation of results, drug availability, and the cost of the test to some extent. No individual NGS platform is ideal for all cancer types or even a specific cancer type at difference disease status. Physicians and patients must have idea about what they expect to get before ordering molecular tests. Conducting precision medicine is an ongoing learning process for physicians, patients, and people in the health care system.

歡迎踴躍參加！

◎每月精彩演講已放到網路上囉，歡迎大家一起來重溫精彩內容！http://speech.ntu.edu.tw/ntuspeech/Cate/index/id-3

◎歡迎加入演講FB社團，掌握最新演講消息：Medical Genetics & Genomics Monthly Seminar https://www.facebook.com/groups/1109733759041652/

臺大基蛋所　與臺大醫院基因醫學部　敬邀

19/01/2026

📣2/9演講歡迎踴躍參加📣
👍另在「2/2有兩場重要外賓」演講：https://reurl.cc/W8Zg9O
--------------------------------------------------------------------------
[講題]：From Embryos to Pathology: Zebrafish Illuminating the Origins of Human Disease

[講者]：李士傑教授（臺大生科系）

CV：https://www.mc.ntu.edu.tw/medgenpro/News.action?q_type=-1&q_itemCode=11312

[時間]：2026/2/9 (星期一) 上午11：20-12：10

[Hybrid Meeting]:
*地點: 醫學院基醫大樓202講堂
*Webex:

https://ntumc.webex.com/ntumc-tc/j.php?MTID=mb15539d23472f963e132dba3e656e465

[摘要]：

The zebrafish (Danio rerio) has become an increasingly important vertebrate model for investigating the developmental origins and mechanisms of human diseases. Many congenital and early-onset disorders arise from disruptions in embryonic processes such as cell fate specification, tissue morphogenesis, and organ maturation. The zebrafish offers a unique opportunity to directly observe these processes in a living organism, as its embryos develop externally, rapidly, and with optical transparency, allowing real-time visualization of disease-relevant cellular and physiological defects.

Genetically, zebrafish exhibit strong conservation with humans, with most disease-associated pathways and a majority of human genes represented in the zebrafish genome. Modern genome-editing approaches, particularly CRISPR/Cas9, enable efficient generation of loss- and gain-of-function models that recapitulate key features of human diseases. Zebrafish models have been widely applied to study neurodevelopmental disorders, cardiovascular and metabolic diseases, cancer, and rare genetic syndromes, often revealing early pathogenic events that are difficult to capture in mammalian systems.

Beyond genetic diseases, zebrafish are highly suited for functional screening of disease modifiers and therapeutic compounds. Their small size and high reproductive capacity support in vivo drug screening and toxicity testing at scales not feasible in rodents. Importantly, disease phenotypes can be assessed at molecular, cellular, and whole-organism levels within a matter of days.

By integrating embryonic biology with disease modeling, zebrafish provide a powerful platform for identifying pathogenic mechanisms, biomarkers, and therapeutic targets. This model system thus plays a critical role in bridging basic developmental research with translational and precision medicine efforts.

歡迎踴躍參加！

◎每月精彩演講已放到網路上囉，歡迎大家一起來重溫精彩內容！http://speech.ntu.edu.tw/ntuspeech/Cate/index/id-3

◎歡迎加入演講FB社團，掌握最新演講消息：Medical Genetics & Genomics Monthly Seminar https://www.facebook.com/groups/1109733759041652/

臺大基蛋所與臺大醫院基因醫學部敬邀

15/01/2026

🎉115年2月2日本所在[臺大醫學院202講堂]舉辦以下兩場演講，歡迎踴躍參加！🎉

【第一場：上午10:20-11:10】

Molecular Profiling of Synapses in the Developing Brain

Prof. Urte Neniskyte
（Professor and Group Leader at the VU LSC-EMBL Partnership Institute for Genome Editing Technologies, Lithuania）
----------------------------------------------------------------------
【第二場：上午11:20-12:10】

Biophysical Approaches to Study Lipid-Protein Interactions

Dr. Rima Budvytyte
（Senior Research Fellow Head of Department of Bioelectrochemistry and Biospectroscopy, Vilnius U., Life Science Center, Lithuania）

上述演講CV及摘要請見：https://www.mc.ntu.edu.tw/medgenpro/News.action?q_type=-1&q_itemCode=11254

臺大基蛋所 & 國科會A4基因轉殖鼠核心設施敬邀

22/12/2025

📣1/12演講歡迎踴躍參加📣

[講題]：Exploring the Future of Extracellular Vesicle Research in Cancer Diagnosis and Therapy

[講者]：程吉安助理教授（臺大藥學系）

CV：https://www.mc.ntu.edu.tw/medgenpro/News.action?q_type=-1&q_itemCode=11252

[時間]：2026/1/12 (星期一) 上午11：20-12：10

[Hybrid Meeting]:
*地點: 醫學院基醫大樓202講堂
*Webex:

https://ntumc.webex.com/ntumc-tc/j.php?MTID=m4fa54971a3e3d8ffe650e8620ed0d2d4

[摘要]：

Extracellular vesicle (EV) research is rapidly advancing from fundamental science to translational applications in EV-based personalized therapeutics and diagnostics. Yet, fundamental questions persist regarding EV biology and mechanisms, particularly concerning the heterogeneous interactions between EVs and cells. Recognizing the multilayered heterogeneity of EVs as both a challenge and an opportunity, in my presentation, I will highlight three exciting EV technological advancements developed by our multidisciplinary group. Especially, these newly developed technologies address technical gaps in dissecting the molecular contents of EV subsets. We believe these approaches could advance our understanding of diverse EV biology and accelerate EV-based personalized diagnostics and therapeutics.

歡迎踴躍參加！

◎每月精彩演講已放到網路上囉，歡迎大家一起來重溫精彩內容！http://speech.ntu.edu.tw/ntuspeech/Cate/index/id-3

◎歡迎加入演講FB社團，掌握最新演講消息：Medical Genetics & Genomics Monthly Seminar https://www.facebook.com/groups/1109733759041652/

臺大基蛋所與臺大醫院基因醫學部敬邀

10/12/2025

=== 演講及研討會資訊，歡迎轉貼幫忙宣傳 ===
=== 也歡迎利用其他平台或是 email 分享給不在 Facebook 的同好 ===
=== 純實體，無線上也無錄影 ===
我們將在 2025-12-18 (星期四) 14:30-16:30 舉辦一個 mini-symposium，主題是 Big Data for Precision Health。前一小時在臺大醫學院 202 講堂，是兩位演講者演講；後一小時在臺大醫學院 203 會議室，是綜合討論。
Prof. Zhongming Zhao 的演講題目是 The Road to Precision Health: Harnessing Big Data.
Prof. Wei Chen 的演講題目是 Decoding Complex Diseases Through Multi-scale Multi-omics.

Prof. Zhao 在 translational bioinformatics, genomics, and precision medicine 等領域有卓著貢獻。目前任職於 The University of Texas Health Science Center at Houston (UTHealth Houston), 是 Chair Professor for Precision Health, McWilliams School of Biomedical Informatics, Founding Director, Center for Precision Health, Vice President for Cancer Genomic Medicine, Professor, Department of Epidemiology, Human Genetics and Environmental Sciences. 發表了超過 500 篇的學術論文，H-index 超過 80，總引用數超過 30,000 次。

Prof. Chen 在 statistical genetics and computational biology 領域相當有突破，尤其是將進階統計運用在高通量基因體資料上。目前任職於 University of Pittsburgh, 是 Professor, Department of Pediatrics, 以及 Department of Human Genetics. 也擔任 Director, Statistical Genetics Core, Department of Pediatrics。

兩位講者的精簡版 CV 可由以下連結下載：https://www.dropbox.com/scl/fi/r2w6w9w6onypazdszpw0c/Biosketches.pdf?rlkey=cmosrevv1zmv4tzocuxcef5ah&dl=0

兩位演講者是受邀來臺灣參加 Joint Meetings of 2025 Taipei International Statistical Symposium and the 13th ICSA International Conference (https://www3.stat.sinica.edu.tw/joint2025/index.html)，因此我們才有機會趁機邀請兩位前來臺大演講及交流。也感謝中研院李文雄院士介紹，我們才有機會認識 Prof. Zhao。

一個小時的演講結束之後，還有完整一個小時的座談會。應該可以充分認識、充分討論。相信對於老師、研究者、醫療人員、博後、學生等等都會是很好的機會。除了想法的交流外，一定也會是好的合作的起點。

05/12/2025

115學年度基蛋所「碩士班一般入學考試」招生開始囉！
竭誠的歡迎你加入本所，與我們一起探尋轉譯醫學的奧妙！！
◎報名自12月2日至12月9日止
◎簡章及報名網址：https://exam.aca.ntu.edu.tw/grab/
◎本所官網：https://www.mc.ntu.edu.tw/medgenpro/Index.action

24/11/2025

📣12/8演講歡迎踴躍參加📣

[講題]：利用TPMI建立多基因風險分數

[講者]：范盛娟研究員（中研院生物醫學科學研究所）
CV:https://www.mc.ntu.edu.tw/medgenpro/News.action?q_type=-1&q_itemCode=11161

[時間]：2025/12/8 (星期一) 上午11：20-12：10

[Hybrid Meeting]:
*地點: 醫學院基醫大樓202講堂
*Webex:
https://nationaltaiwanuniversitycollegeofmedicine.webex.com/nationaltaiwanuniversitycollegeofmedicine-tc/j.php?MTID=m095fa4a2b4c5c455d6b9e4a9cb4d2e08

[摘要]：
The Taiwan Precision Medicine Initiative (TPMI) provides an unprecedented national resource for generating population-specific polygenic risk scores (PRS). With over 486,000 participants who contributed both genomic profiles and comprehensive clinical records, TPMI represents one of the world's largest and most genetically homogeneous biobank cohorts. This large-scale dataset enables the construction of accurate PRS tailored to the Taiwanese population, addressing the well-recognized problem that PRS models developed from European datasets often perform poorly in Asian groups.
The presentation introduces PRS as a method that aggregates the effects of hundreds of thousands of common genetic variants (SNPs) to quantify an individual's inherited susceptibility to complex diseases. By leveraging genome-wide association studies (GWAS) and algorithms such as LDpred2 and
PRSmix+, TPMI generates disease-specific and multi-trait PRS models PRSmix+capable of predicting risk across cardiovascular-metabolic diseases, autoimmune disorders, and kidney-related conditions. The results demonstrate that TPMI-derived PRS generally outperform models trained in European cohorts, underscoring the necessity of population-matched genomic resources.
Performance varies across disease categories: cardiovascular and autoimmune diseases show moderate predictive accuracy, whereas kidney-related traits remain challenging due to modest heritability and complex comorbidity patterns. Nevertheless, TPMI's large sample size has enabled the discovery of novel loci and strengthened risk stratification capabilities.
Looking forward, TPMI PRS offers strong potential for clinical translation, including early screening, personalized prevention strategies, lifestyle guidance, and integration with AI-driven multi-omic health prediction. The initiative represents a foundational step toward precision health in Taiwan, paving the way for equitable and population-specific genomic medicine.

歡迎踴躍參加！

◎每月精彩演講已放到網路上囉，歡迎大家一起來重溫精彩內容！http://speech.ntu.edu.tw/ntuspeech/Cate/index/id-3

◎歡迎加入演講FB社團，掌握最新演講消息：Medical Genetics & Genomics Monthly Seminar https://www.facebook.com/groups/1109733759041652/

臺大基蛋所與臺大醫院基因醫學部敬邀

Address

Zhongshan District

Website

https://www.mc.ntu.edu.tw/medgenpro/Index.action

Alerts

Be the first to know and let us send you an email when 臺大基因體暨蛋白體醫學研究所（基蛋所） posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The University

Send a message to 臺大基因體暨蛋白體醫學研究所（基蛋所）:

Shortcuts

Want your university to be the top-listed University in Zhongshan District?